azathioprine has been researched along with Giant Cell Arteritis in 26 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Giant Cell Arteritis: A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year." | 9.06 | Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. ( De Silva, M; Hazleman, BL, 1986) |
| "The aim of this bicentric retrospective study was to describe the use of azathioprine in giant cell arteritis, and to appreciate its corticosteroid-sparing effect in glucocorticoid-dependent patients or with severe glucocorticoid related side effects." | 7.83 | [Place of azathioprine in the treatment of giant cell arteritis]. ( Agard, C; Boureau, AS; De Decker, L; de Faucal, P; Espitia, O, 2016) |
| "The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year." | 5.06 | Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. ( De Silva, M; Hazleman, BL, 1986) |
| "The aim of this bicentric retrospective study was to describe the use of azathioprine in giant cell arteritis, and to appreciate its corticosteroid-sparing effect in glucocorticoid-dependent patients or with severe glucocorticoid related side effects." | 3.83 | [Place of azathioprine in the treatment of giant cell arteritis]. ( Agard, C; Boureau, AS; De Decker, L; de Faucal, P; Espitia, O, 2016) |
| "Giant cell arteritis is a chronic vasculitis affecting large and medium-sized arteries, most commonly the temporal and other cranial arteries." | 2.48 | Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. ( Borchers, AT; Gershwin, ME, 2012) |
| "Clinicians who treat patients with giant cell arteritis (GCA) face many unresolved challenges." | 2.44 | Five clinical conundrums in the management of giant cell arteritis. ( Cid, MC; Espígol-Frigolé, G; García-Martínez, A; Hernández-Rodríguez, J; Lozano, E, 2007) |
| " To achieve maximal efficacy but minimize glucocorticoid-related adverse reactions, dosage should be individually tailored." | 2.44 | Improving therapeutic options for patients with giant cell arteritis. ( Pipitone, N; Salvarani, C, 2008) |
| "When unrecognized and therefore untreated, vasculitis of the nervous system leads to pervasive injury and disability making this a disorder of paramount importance to all clinicians." | 2.42 | Vasculitis of the nervous system. ( Younger, DS, 2004) |
| "Polymyalgia rheumatica (PMR)/temporal arteritis (TA) frequently causes significant morbidity in patients older than 50 years of age." | 2.41 | Polymyalgia rheumatica/temporal arteritis: recent advances. ( Barilla-LaBarca, ML; Brasington, RD; Lenschow, DJ, 2002) |
| "Corticosteroids remain the cornerstone treatment of giant cell arteritis." | 2.40 | [Immunosuppressive agents in Horton's disease. Which drug for which indication?]. ( Roblot, P, 1998) |
| "He had been diagnosed with temporal arteritis 12 years earlier." | 1.48 | Hypertrophic pachymeningoencephalitis associated with temporal giant cell arteritis. ( Boisch, G; Duda, S; Hartmann, C; Weßling, H, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (26.92) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 9 (34.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boisch, G | 1 |
| Duda, S | 1 |
| Hartmann, C | 1 |
| Weßling, H | 1 |
| Samson, M | 2 |
| Greigert, H | 1 |
| Ghesquière, T | 1 |
| Bonnotte, B | 1 |
| Boureau, AS | 1 |
| de Faucal, P | 1 |
| Espitia, O | 1 |
| De Decker, L | 1 |
| Agard, C | 1 |
| Watelet, B | 1 |
| de Boysson, H | 1 |
| Bienvenu, B | 1 |
| Muratore, F | 1 |
| Pipitone, N | 2 |
| Salvarani, C | 2 |
| Cantoni, N | 1 |
| Meyer, P | 1 |
| Katan, M | 1 |
| Kappos, L | 2 |
| Hess, C | 1 |
| Daikeler, T | 1 |
| McWilliams, ET | 1 |
| Dickinson, KK | 1 |
| Walker, DM | 1 |
| Raman, V | 1 |
| Borchers, AT | 1 |
| Gershwin, ME | 1 |
| Moll, R | 1 |
| Hameed, B | 1 |
| Schnabel, A | 1 |
| Roelcke, U | 1 |
| Eschle, D | 1 |
| Moschopulos, M | 1 |
| Laeng, RH | 1 |
| Buettner, UW | 1 |
| Younger, DS | 1 |
| Cid, MC | 1 |
| García-Martínez, A | 1 |
| Lozano, E | 1 |
| Espígol-Frigolé, G | 1 |
| Hernández-Rodríguez, J | 1 |
| Kaeser, HE | 1 |
| Roblot, P | 1 |
| Barilla-LaBarca, ML | 1 |
| Lenschow, DJ | 1 |
| Brasington, RD | 1 |
| Airò, P | 1 |
| Antonioli, CM | 1 |
| Vianelli, M | 1 |
| Toniati, P | 1 |
| Hoffman, GS | 1 |
| Alexander, M | 1 |
| Kampf, D | 1 |
| Lovschall, S | 1 |
| Wenig, C | 1 |
| Meiser, RJ | 1 |
| Roig López de los Mozos, A | 1 |
| Calvo Catalá, J | 1 |
| Hortelano Martínez, E | 1 |
| Liñana Santafé, JJ | 1 |
| González-Cruz Cervellera, MI | 1 |
| Ballester Belda, JE | 1 |
| De Silva, M | 1 |
| Hazleman, BL | 1 |
| Sölch, G | 1 |
| Kiesewetter, R | 1 |
| Kaiser, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO[NCT03841734] | Phase 3 | 8 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for azathioprine and Giant Cell Arteritis
| Article | Year |
|---|---|
[Treatment of giant cell arteritis].
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Azat | 2019 |
Treatment of giant-cell arteritis, a literature review.
Topics: Antirheumatic Agents; Azathioprine; Drug Therapy, Combination; Drug-Related Side Effects and Adverse | 2017 |
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.
Topics: Animals; Antibodies, Monoclonal; Azathioprine; Biological Therapy; Clinical Trials as Topic; Giant C | 2017 |
Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment.
Topics: Aorta; Aortic Aneurysm; Aspirin; Azathioprine; Dendritic Cells; Female; Giant Cell Arteritis; Humans | 2012 |
Vasculitis of the nervous system.
Topics: Azathioprine; Connective Tissue Diseases; Cyclophosphamide; Diagnosis, Differential; Giant Cell Arte | 2004 |
Five clinical conundrums in the management of giant cell arteritis.
Topics: Abortifacient Agents, Nonsteroidal; Aorta; Aortography; Azathioprine; Dilatation, Pathologic; Giant | 2007 |
Improving therapeutic options for patients with giant cell arteritis.
Topics: Antibodies, Monoclonal; Azathioprine; Dose-Response Relationship, Drug; Drug Administration Schedule | 2008 |
[Immunosuppressive agents in Horton's disease. Which drug for which indication?].
Topics: Anti-Inflammatory Agents; Azathioprine; Drug Resistance; Giant Cell Arteritis; Humans; Immunosuppres | 1998 |
Polymyalgia rheumatica/temporal arteritis: recent advances.
Topics: Adrenal Cortex Hormones; Aged; Azathioprine; Cyclophosphamide; Dose-Response Relationship, Drug; Dru | 2002 |
Treatment of giant-cell arteritis: where we have been and why we must move on.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Aortic Aneurysm; Azathioprine; Drug Therapy, Combina | 2002 |
2 trials available for azathioprine and Giant Cell Arteritis
| Article | Year |
|---|---|
Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs.
Topics: Aged; Antibodies, Monoclonal; Antirheumatic Agents; Azathioprine; Drug Resistance; Drug Therapy, Com | 2002 |
Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.
Topics: Aged; Azathioprine; Clinical Trials as Topic; Double-Blind Method; Female; Giant Cell Arteritis; Hum | 1986 |
14 other studies available for azathioprine and Giant Cell Arteritis
| Article | Year |
|---|---|
Hypertrophic pachymeningoencephalitis associated with temporal giant cell arteritis.
Topics: Aged, 80 and over; Antirheumatic Agents; Azathioprine; Craniotomy; Diagnosis, Differential; Dura Mat | 2018 |
[Place of azathioprine in the treatment of giant cell arteritis].
Topics: Aged; Aged, 80 and over; Azathioprine; Drug Resistance; Female; France; Giant Cell Arteritis; Humans | 2016 |
A confusing patient's history: small or large vessel vasculitis?
Topics: Autoantibodies; Azathioprine; Conjunctivitis; Cyclophosphamide; Diagnosis, Differential; Drug Therap | 2010 |
Acute inflammatory aortitis: utility of hybrid imaging with positron emission tomography/computed tomography in diagnosis and follow-up.
Topics: Acute Disease; Aortitis; Azathioprine; Biopsy; Drug Therapy, Combination; Female; Fluorodeoxyglucose | 2012 |
A case of Takayasu arteritis diagnosed at early-phase of disease by conventional CT scanning.
Topics: Adult; Aorta; Aortitis; Atherosclerosis; Azathioprine; Behcet Syndrome; Diagnosis, Differential; Dos | 2012 |
[Corticosteroid saving-up in giant cell arteritis?].
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Azathioprine; Cycloph | 2002 |
Meningoradiculitis associated with giant cell arteritis.
Topics: Anti-Inflammatory Agents; Azathioprine; Cranial Nerve Diseases; Cyclophosphamide; Giant Cell Arterit | 2002 |
Cytostatic drugs in the treatment of severe vasculitides. Indications, results and risks.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Azathioprine; Cyclophosphamide; Drug Therapy, Combin | 1984 |
[Hyperergic collagenoses. Clinical aspects, differential diagnosis and therapy (author's transl)].
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Child; Collagen Diseases; Cyclophosphamide; Derm | 1977 |
[Azathioprine in the treatment of temporal arteritis and polymyalgia rheumatica].
Topics: Aged; Azathioprine; Back Pain; Drug Evaluation; Drug Therapy, Combination; Female; Fractures, Sponta | 1977 |
[Azathioprine in the treatment of arteriitis temporalis].
Topics: Aged; Autoimmune Diseases; Azathioprine; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1975 |
[Immunosuppressor treatment in temporal arteritis of long-term evolution].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chronic Disease; Female; Giant Cell Art | 1992 |
[Temporal arteritis--inflammatory vascular disease of the higher age].
Topics: Age Factors; Aged; Anticoagulants; Azathioprine; Blindness; Female; Giant Cell Arteritis; Humans; Pr | 1974 |
[Polymyalgia rheumatica].
Topics: Age Factors; Aged; Autoimmune Diseases; Azathioprine; Biopsy; Female; Giant Cell Arteritis; Humans; | 1974 |